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Abstract
Background: Identifying people at higher risk of developing tuberculosis with human immunodeficiency virus (HIV)
infection may improve clinical management of co-infections. Iron influences tuberculosis (TB) pathogenesis, but
understanding the exact mechanisms of how and timing of when iron is involved remains challenging since
biological samples are rarely available from the disease susceptibility period due to the difficulty in predicting in
who and when, if ever, TB will develop. The objective of this research was to determine how host iron status
measured at HIV diagnosis and genotypes related to host iron metabolism were associated with incident TB.
Methods: Archived clinical data, plasma and DNA were analyzed from 1139 adult participants in a large HIV-1,
HIV-2 and dual seroprevalent cohort based at the Medical Research Council Laboratories in The Gambia. Incident
pulmonary and/or extrapulmonary TB diagnoses a minimum of 28 days after HIV diagnosis were independently
re-confirmed using available evidence (n=152). Multiple host iron status biomarkers, Haptoglobin and solute carrier
family 11, member 1 (SLC11A1) genotypes were modeled to characterize how indicators of host iron metabolism
were associated with TB susceptibility.
Results: Hemoglobin (incidence rate ratio, IRR=0.88, 95% CI=0.79-0.98), plasma transferrin (IRR=0.53, 0.33-0.84) and
ferritin (IRR=1.26, 1.05-1.51) were significantly associated with TB after adjusting for TB susceptibility factors. While
genotype associations were not statistically significant, SLC11A1 associations replicated similar directions as reported
in HIV-seronegative meta-analyses.
Conclusions: Evidence of host iron redistribution at HIV diagnosis was associated with incident TB, and genetic
influences on iron homeostasis may be involved. Low hemoglobin was associated with subsequent diagnosis of TB,
but when considered in combination with additional iron status biomarkers, the collective findings point to a
mechanism whereby anemia and iron redistribution are likely due to viral and/or bacteria-driven processes and the
host immune response to infection. As a result, iron supplementation may not be efficacious or safe under these
circumstances. Clinical and nutritional management of HIV and Mycobacterium tuberculosis co-infected individuals,
especially in regions where food insecurity and malnutrition co-exist, may be further improved when the
iron-related TB risk factors identified here are better understood and managed to favor host rather than pathogen
outcomes.
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Background
In 2011, an estimated 8.7 million new cases of tubercu-
losis (TB) arose from the approximately 1/3 of the
world’s population infected with Mycobacterium tuber-
culosis (Mtb) [1]. This is an enormous disease burden,
but it also underscores that infection with Mtb alone is
insufficient to cause TB disease since the vast majority
successfully contain their infection as indicated by the
cumulative lifetime TB risk approximated between 5 to
10% in the absence of human immunodeficiency virus
(HIV) co-infection [2]. Among the subgroup of Mtb-
infected individuals that do progress to disease rapidly
after initial infection or after a long period of clinical la-
tency, there are dynamic and complex interactions that
occur between multiple host and pathogen factors that
must ultimately tip the balance towards disease occur-
rence. While some risk factors like HIV co-infection are
well recognized, other risk factors like nutritional status
of the host (or pathogen) have thus far been poorly
characterized.
Like the human host and other microbes, Mtb has
developed an intricate system of acquiring, metabolizing
and storing essential iron under host-imposed states of
iron deficiency and excess. Despite host attempts to re-
strict available iron to the microbe, Mtb is very success-
ful in accessing multiple host iron sources including
lactoferrin, ferritin and transferrin (Tf) [3], and recent
evidence has revealed iron can also be obtained via a
heme-acquisition system [4,5]. Host mechanisms also
thwart bacterial iron acquisition and examples include
host siderocalin binding to iron-laden Mtb siderophores
that have captured host iron [6], plasma haptoglobin
(Hp) binding free hemoglobin (Hb) to reduce host per-
ipheral iron availability [7], increasing hepcidin-mediated
ferroportin degradation to impair host iron efflux from
intestinal enterocytes and macrophages [8], and altering
host macrophage iron concentrations via the solute car-
rier 11 family of genes that encode proteins involved in
phagolysosomal iron transport [9].
Host iron status and iron trafficking between the host
and pathogen may affect the critical host-pathogen battle
for essential iron, and thereby influence the development
of TB. We hypothesized that the risk of TB in people liv-
ing with HIV infection increases with elevated host iron
status, increased macrophage iron availability and subopti-
mal regulation of iron distribution (Additional file 1). The
primary research objective of this study was to describe
how host iron status at HIV diagnosis indicated by plasma
iron status biomarkers and iron-genes, including solute
carrier family 11 (proton-coupled divalent metal ion trans-
porters), member 1 (SLC11A1) operating at the level of
the macrophage, were associated with the later develop-
ment of TB in HIV infection. The main purpose of this
study was to understand which iron status biomarkers
were associated with TB risk in HIV infection in order to
further the understanding of biomarker profiles that pre-
dict TB risk, and to guide evidence-based nutritional and
clinical management of iron status among people with
HIV infection who are also at risk of developing TB. To
our knowledge, Haptoglobin genotypes have not been
reported in association with incident TB in HIV infection,
and SLC11A1 genotypes have been restricted primarily to
investigating TB susceptibility among HIV-seronegative
participants. This research demonstrates that iron redistri-
bution at the time of HIV diagnosis is associated with a
significantly greater probability of developing TB, and
SLC11A1 genotypes may influence TB susceptibility in
individuals with HIV co-infection like has been demon-
strated among HIV-negative individuals [10].
Methods
Study setting
Archived data and biological samples were obtained
from the HIV Clinical Cohort based at The Medical Re-
search Council (MRC) Laboratories in The Gambia. The
first HIV infection was detected in The Gambia in 1986,
and this prospective cohort was established shortly
thereafter to study the emerging HIV-1, HIV-2 and HIV-
dual infection epidemics unique to this region. Cohort
participants were recruited nation-wide and all were
offered free clinical care according to Gambian national
guidelines in effect at the time of their participation, in-
cluding co-trimoxazole prophylaxis and symptom man-
agement. For the participants included in the current
study, anti-retroviral therapy and viral load data were
unavailable at that time.
Study design
Eligibility for this retrospective cohort study included all
HIV Clinical Cohort participants who: i) were ≥18 years; ii)
had an archived baseline plasma sample stored at –20
to –80°C and collected within 90 days of cohort entry
and additionally, if they were diagnosed with incident
TB, if their plasma sample was taken >28 days before
TB diagnosis; and iii) had an archived buffy coat or
PBMC sample stored at –80°C or in liquid nitrogen
that was available for DNA extraction. To establish inci-
dent TB cases for this study, two physicians supervised
the re-examination of all original clinical, microbiological
and radiographic evidence for cohort participants who
had a provisional TB diagnoses recorded between 01/01/
1991-31/12/2001 in order to confirm the original TB diag-
nosis. First instances of the following were classified as in-
cident TB: confirmed pulmonary TB (PTB) defined by the
presence of acid-fast bacilli in direct smear or culture
from sputum or lavage, or smear-negative PTB defined by
the presence of strongly suggestive clinical symptoms and
radiographic signs consistent with PTB; and/or confirmed
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extra-pulmonary TB (EPTB) defined by the demonstration
of acid-fast bacilli in a biopsy or aspirate of a lymph node,
or any other normally sterile site by smear or culture, or
probable EPTB defined by strongly suggestive clinical fea-
tures of EPTB. Participants with prevalent disease (i.e. any
form of TB diagnosed ≤28 days following HIV diagnosis)
were excluded from this study. Cohort follow-up of parti-
cipants occurred at regularly scheduled clinic visits, or
when participants presented for clinical care at any time.
If participants failed to return to the clinic, fieldworkers
visited their residence throughout the country to ascertain
their mortality status. Censoring of data occurred when
one of the mutually exclusive events occurred: end of the
study follow-up period; first instance of TB; death or loss
to follow-up defined as the last date known with certainty
to be alive.
Laboratory protocols
Details of iron and candidate gene analyses have been
previously published [11]. Briefly, soluble transferrin re-
ceptor (sTfR) (R&D Systems, Abingdon, UK) and ferritin
(Immuno-biological Laboratories, Hamburg, Germany)
were measured by enzyme-linked immune-sorbent assay
(ELISA). Plasma iron was assessed using an endpoint
assay (ABX Diagnostics, Shefford, UK) and Tf by turbid-
imetry (ABX Diagnostics, Shefford, UK). Hemoglobin
(Hb) concentrations were measured during routine clin-
ical screening and obtained from study databases.
Alpha-1-antichymotrypsin (ACT) was measured using a
nephelometric assay (DakoCytomation Inc, Ely, UK).
DNA extraction occurred at the MRC Laboratories in
The Gambia, and all genotyping was performed at the Well-
come Trust Centre for Human Genetics in Oxford. HP
genotyping was performed using an allele-specific polymer-
ase chain reaction (PCR)–based method distinguishing the
major allelic variants (Hp1 and Hp2) of the α-chain [12].
SLC11A1 polymorphisms SLC1 (rs34448891) and CAAA
(rs17229009) were genotyped by fluorescent polyacrylamide
gel electrophoresis of amplicons on an ABI 3700 sequencer
(Perkin Elmer-ABI, Foster City, USA). SLC3 (rs3731865),
SLC6a (rs17235409) and SLC6b (rs17235416) were geno-
typed using the Sequenom platform (hME Sequenom,
http://www.sequenom.com). Internal control samples were
included during genotyping for quality control.
Statistical analysis
The primary outcome was incident TB, with main effects
for iron status or iron-metabolism genotypes assessed
using complete data with multiplicative Poisson regression
models and differences estimated on a log scale and
expressed as incidence rate ratios (IRR) (Stata MP 11.2,
Statacorp, Texas, USA). Potential confounders considered
a priori were HIV-type, sex, self-reported ethnicity (for
genotype associations) and baseline absolute CD4 cell
count, age, body mass index (BMI) [13] and ACT concen-
trations. Genotype data was assessed based on dominant
models, and adjustments were not made for multiple test-
ing as the genotypes selected here were based on a prior
hypotheses rather than data-driven or post-hoc analyses.
Missing data on potential confounders (self-reported eth-
nicity, hemoglobin, BMI, CD4) and genotyping failures for
some subjects influenced the ability to detect statistical
significance in regression models that included these vari-
ables. Sensitivity analyses were conducted including
microbiologically-confirmed cases of TB only versus all
TB cases that included a clinical diagnosis, and as the
overall interpretation was not altered all TB cases were
included in all analyses.
Ethics considerations
Ethical approval for this study was granted by the ethical
committees of the Joint Gambian Government/MRC La-
boratories, the London School of Hygiene & Tropical
Medicine and Cornell University. All participants pro-
vided voluntary written informed consent when enrol-
ling in the main MRC HIV Clinical Cohort and the
original consent form used was included as part of the
ethical review for this study.
Results
Incident TB
Of the 1139 individuals eligible for this study, the median
time-to-TB diagnosis following cohort entry at first HIV
diagnosis was approximately six months (interquartile
range = 4 to 8 months), with microbiologically-confirmed
PTB the most common TB diagnosis (n = 107/152 inci-
dent TB cases) (Table 1). Demographic and clinical char-
acteristics are summarized in Additional file 2. Females
(unadjusted IRR, 95% CI = 0.53, 0.38 to 0.73) and partici-
pants with higher CD4 (unadjusted IRR, 95% CI = 0.56,
0.50 to 0.64) were less likely to develop incident TB, while
those with a BMI < 18.5 kg/m2 were more likely to de-
velop TB (unadjusted IRR, 95% CI = 2.02, 1.33 to 3.08). In
Figure 1, CD4 counts categorized according to clinical cat-
egories (i.e. > 500, 200-500, < 200 cells/mm3) provide clear
evidence that, as expected, greater immunosuppression
was associated with an increased likelihood of developing
TB (P < 0.001).
Iron redistribution is a risk factor for the development of
TB in HIV infection
At baseline, participants that subsequently developed TB
had lower Tf and iron, and higher ferritin concentrations
than participants who did not develop TB (Additional file 2).
Kaplan-Meier curves graphically indicated that this associ-
ation was in a dose-response manner and statistically signifi-
cant for Hb, Tf, iron and ferritin tertile categories (In
Figure 1; all P < 0.001). Univariate regression analyses
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(Table 2, Models 1) indicated inverse associations for
Hb, iron and Tf concentrations (i.e. for each one unit
increase in concentration, there was a significantly
reduced probability of TB), while increased ferritin
concentrations were directly associated with incident
TB (i.e. for each one unit increase in concentration,
there was a significantly increased probability of TB). Nei-
ther sTfR nor transferrin saturation were associated with
incident TB diagnosis. In Table 2, Models 2, adjusting for
the acute phase response (APR) assessed by ACT concen-
tration only slightly modified the magnitude of observed
effects compared to the unadjusted models, and did not
alter the overall interpretation. Likewise, even after adjust-
ing for several known risk factors for TB (BMI, absolute
CD4 cell count, age, sex: Table 2, Models 3), Tf, ferritin
and Hb concentrations remained significantly associated
with the development of TB in HIV infection.
Iron-related genotypes and the development of TB in HIV
infection
Regression analyses of unadjusted and adjusted models
of iron-metabolism genotypes were not statistically sig-
nificant (Table 3). In Table 3 Models 2, adjusting for a
number of known risk factors for TB (baseline BMI, ab-
solute CD4 cell count, age, sex) considerably modified
the magnitude of effect of carriage of the TB predispos-
ing minor allele for SLC1 (rs34448891) and SLC3
(rs3731865), however, these associations were not statis-
tically significant.
Discussion
This study provides evidence that iron status measured
by biomarkers associated with distinct roles in iron me-
tabolism and homeostasis are risk factors for developing
incident TB in immunocompromised HIV-infected indi-
viduals. To our knowledge, this data demonstrates for
the first time in a human cohort study the temporal as-
sociation whereby iron status assessed prior to TB diag-
nosis is associated with susceptibility to TB, rather than
the more commonly studied associations reported at TB
diagnosis or in relation to post-TB diagnosis clinical out-
comes [14-17]. The pattern of iron status biomarkers we
observed is characteristic of iron redistribution occur-
ring with anemia of chronic disease/anemia of inflam-
mation. This suggests a complicated mechanistic process
whereby TB risk may be related to differential host iron
handling and/or bacterial iron availability in the sub-
group of people with Mtb and HIV co-infections who
are susceptible to TB.
An iron-related risk profile observed in this study is
characteristic of anemia of inflammation mediated by
the APR, and since all cohort participants were HIV-
seropositive and living with a chronic infection, most
participants were experiencing varying degrees of APR.
During the APR, inflammatory cytokines mediate the re-
distribution of body iron from the systemic circulation to
macrophage iron stores, with resulting inhibition of
erythropoiesis. Under conditions of APR, hepcidin would
be rapidly induced through both interleukin (IL)-6 and
bone morphogenetic protein dependent pathways result-
ing in the inhibition of ferroportin-mediated iron efflux
from enterocytes and macrophages [18-20]. Overall,
APR results in reduced dietary iron uptake, reduced
erythropoeisis and, importantly, increased macrophage
iron retention [21]. It is the consequences of this iron
redistribution that may alter both the host innate im-
mune response to infection [22] and Mtb virulence
through an increased ability of Mtb to access increas-
ingly available host iron sources. Macrophage iron
concentration may favor intracellular pathogens, per-
haps explaining Mtb’s niche environment within the
macrophage. Although we have not measured plasma
Table 1 Cohort follow-up and frequency of tuberculosis diagnoses
Number of cohort participants 1139
Person-years of follow-up 2708
Median days to incident tuberculosis
diagnosis, interquartile range
173 (114-237)
Tuberculosis diagnoses Number of incident
tuberculosis cases
Percentage of all incident
tuberculosis casescxx
Percentage of HIV Clinical Cohort
participants in this study
Tuberculosis, all cases 152 100 13
Pulmonary, all cases 135 89 12
Pulmonary, culture-confirmed 27 18 2
Pulmonary, sputum-positive 80 53 7
Pulmonary, sputum-negative 44 26 4
Extra-pulmonary tuberculosis, all cases 23 15 2
Extra-pulmonary, culture-confirmed 13 9 1
Extra-pulmonary, probable 10 7 1
*Pulmonary and extra-pulmonary tuberculosis classifications were not mutually exclusive, therefore percentage totals may not sum to 100%.
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hepcidin concentrations or directly measured macro-
phage iron in this study, in vitro and animal model
data indicates iron influences the development of TB
and iron-loaded macrophages promote Mycobacterium
growth [23-27]. Overall, our data provide support for a
working hypothesis that host iron redistribution favors
pathogen virulence at the dynamic and evolving host-
pathogen interface. It is likely that each iron factor is
associated with known and yet unknown roles in iron














































































































Figure 1 Risk of incident tuberculosis in HIV according to absolute CD4 cell count and iron biomarkers.
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Table 2 Host iron as a risk factor for incident tuberculosis in HIV infection
Model 1: IRR, unadjusted Model 2: IRR, adjusted for acute phase response Model 3: IRR, adjusted for known
TB risk factors*
Is the host iron status
biomarker a risk factor
for incident TB in HIV
infection?
Does the biomarker remain an
independent risk factor after adjusting
for a marker of the host acute phase
response (baseline α-1-
antichymotrypsin concentration)?
Does the biomarker remain an
independent risk factor for
incident TB in HIV infection after
adjusting for baseline age, CD4,
body mass index?
Iron factors IRR (95% CI) P IRR (95% CI) P IRR (95% CI) P
Transferrin, g/L 0.25 (0.19-0.35) < 0.001 0.30 (0.21-0.43) < 0.001 0.53 (0.33-0.84) 0.007
Transferrin saturation, % 1.00 (0.99-1.01) 0.691 1.00 (0.99-1.01) 0.691 1.00 (0.99-1.01) 0.669
Ferritin, μg/L 1.71 (1.49-1.97) < 0.001 1.60 (1.35-1.89) < 0.001 1.26 (1.05-1.51) 0.014
Hemoglobin, g/L 0.79 (0.73-0.86) < 0.001 0.84 (0.77-0.92) < 0.001 0.88 (0.79-0.98) 0.023
Iron, μmol/L 0.92 (0.88-0.95) < 0.001 0.94 (0.91-0.97) < 0.001 0.96 (0.92-1.01) 0.104
Transferrin receptor, nmol/L 1.01 (1.00-1.02) 0.160 1.01 (1.00-1.02) 0.130 1.00 (0.99-1.01) 0.991
Main effects for iron status biomarkers assessed using complete data with multiplicative Poisson regression models with differences estimated on a log scale and
expressed as incidence rate ratios (IRR).
Ferritin and absolute CD4 cell counts were natural-logarithm transformed; BMI was dummy-coded as <18.5 or ≥18.5 kg/m2; self-reported ethnicity was dummy-
coded as Mandinka, Wolof, Fula, Jola or Otherwise.
*In this dataset, unadjusted Poisson regression analyses indicated sex (females) (IRR, 95% CI = 0.53, 0.38 to 0.73), and higher absolute CD4 (IRR, 95% CI = 0.56, 0.50
to 0.64) were associated with significantly lower risk of incident TB and body mass index < 18.5 (IRR, 95% CI = 2.02, 1.33 to 3.08) was associated with a
significantly higher risk of TB. Age (IRR, 95% CI = 1.02, 1.00 to 1.04) was not a direct risk factor for TB in this dataset, but age was included in models as it is
commonly associated with differential risk of TB.
CI = 95% confidence interval; IRR = incidence rate ratio; TB = tuberculosis (all forms).
Table 3 Host iron genotypes as a risk factor for incident tuberculosis in HIV infection
Iron genotypes Model 1: IRR, unadjusted Model 2: IRR, adjusted for known risk factors for TB*
Is the iron genotype a risk factor
for incident TB in HIV infection?
Does the iron genotype remain a risk factor for incident
TB after adjusting for sex, baseline age, CD4, body mass
index plus self-reported ethnicity?
Haptoglobin*
Hp 1-1 Reference Reference
Hp 2-1, Hp 2-2 1.03 (0.68-1.56) 0.879 0.83 (0.47-1.49) 0.525
SLCA11A1
SLC1 (rs34448891) Allele 3/Allele 3 Reference Reference
Allele 3/Other, Other/Other 0.96 (0.65-1.42) 0.832 1.29 (0.73-2.29) 0.377
SLC3 (rs3731865) G/G Reference Reference
C/G, C/C 1.05 (0.65-1.69) 0.853 1.56 (0.85-2.87) 0.151
SLC6a (rs17235409) G/G Reference Reference
A/G, A/A 0.95 (0.54-1.68) 0.869 1.10 (0.51-2.36) 0.813
SLC6b (rs17235416) TGTG +/+ Reference Reference
TGTG +/-, -/- 0.90 (0.59-1.36) 0.610 1.00 (0.56-1.78) 0.996
CAAA (rs17229009) CAAA+/+, +/- Reference Reference
CAAA -/- 0.78 (0.49-1.25) 0.302 0.85 (0.45-1.61) 0.615
Main effects for iron-metabolism genotypes assessed using complete data with multiplicative Poisson regression models with differences estimated on a log scale
and expressed as incidence rate ratios (IRR).
Absolute CD4 cell counts were natural-logarithm transformed; BMI was dummy-coded as <18.5 or ≥18.5 kg/m2; self-reported ethnicity was dummy-coded as
Mandinka, Wolof, Fula, Jola or Otherwise.
*In this dataset, unadjusted Poisson regression analyses indicated sex (females) (IRR, 95% CI = 0.53, 0.38 to 0.73), and higher absolute CD4 (IRR, 95% CI = 0.56, 0.50
to 0.64) were associated with significantly lower risk of incident TB and body mass index < 18.5 (IRR, 95% CI = 2.02, 1.33 to 3.08) was associated with a higher risk
of TB. Age (IRR, 95% CI = 1.02, 1.00 to 1.04) was not a direct risk factor for TB in this dataset, but age was forced in models as it is commonly associated with
differential risk of TB in the literature.
CI = 95% confidence interval; IRR = incidence rate ratio; TB = tuberculosis (all forms).
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iron-regulated/-catalyzed host immune defenses collect-
ively change the risk of disease. It remains unanswered as
to what degree managing iron redistribution during HIV
infection, Mtb infection or co-infection leads to the devel-
opment of TB.
Low Hb concentration and anemia (of unknown eti-
ology) are frequently considered an indication of dietary
iron insufficiency among people living in regions where
malnutrition and food insecurity are common and treated
using supplemental iron. While low Hb concentrations
were associated with an increased risk of developing TB in
this study, by interpreting low Hb in combination with the
other iron and inflammatory markers it is more likely that
anemia was due to reasons other than, or in addition to,
dietary iron insufficiency alone. Similar conclusions were
made in an Indonesian study by Sahiratmadja et al. [14]
where despite the observation that most participants with
TB had anemia of unknown etiology, spontaneous reso-
lution of anemia was associated with TB treatment in the
absence of iron supplementation. Likewise, Lee et al. [28]
reported that anemia was common in Korean participants
with TB, and similarly anemia resolved in 65% of partici-
pants receiving TB medication without iron replacement
therapy, with the remainder having stable (26%) or
improved Hb concentrations (9%) following TB treatment
only.
Using an a priori candidate gene approach, we hypothe-
sized that variation in the HP and SLC11A1 genes would
be associated with incident TB [29] (Additional file 1).
While our data do not show statistically significant find-
ings, the direction and magnitude of associations observed
for SLC11A1 are consistent with reports in African-
Americans [30], South Africans [31] and those from a re-
cent SLC11A1 meta-analysis of studies across different
ethnicities including HIV-negative participants from three
African countries [10]. Li et al. [10] reported a signifi-
cantly increased overall odds of TB was apparent for
SLC1/rs34448891 [Odds ratio, (OR) Allele 3 versus Other-
wise =1.31; 1.08 to 1.59], SLC3/rs3731865 (OR C/C plus
C/G versus G/G =1.23; 1.05 to 1.44), SLC6a/rs17235409
(OR A/A plus A/G versus G/G =1.25; 1.04 to 1.50) and
SLC6b/rs17235416 (OR TGTG -/- plus TGTG +/- versus
TGTG +/+ =1.35; 1.17 to 1.54). In contrast, our SLC11A1
CAAA/rs17229009 results differed in direction to non-
statistically significant results reported from a Malawian
case-control study of HIV-seropositive and HIV-negative
individuals [32]. A recent report has also presented evi-
dence of a significant gene-gene interaction with SLC11A1
and IFNG1 among South Africans [33]. A number of
Russian and Ukrainian studies have reported on Hp phe-
notypes and TB diagnosis or prognosis (reviewed in [29])
however, no differences in Hp phenotypes were observed
between PTB cases and controls from Zimbabwe [34]. To
our knowledge, however, this is the first study to report
data for HP genotypes and TB susceptibility. Ultimately,
as is the case for many individual genetic associations,
studies, cumulative data from multiple studies will be im-
portant to unravel the true genetic associations and TB
susceptibility, including the likely possibility of iron-gene
interactions and that have been previously reported for
HIV mortality from the MRC HIV Clinical Cohort [11].
The current study has strength in that the cohort de-
sign which allows temporal associations to be ascer-
tained. However, it is possible that prevalent TB
remained undetected at the time of blood sampling
among some participants. This would likely have biased
to the null, but overall it was likely to have a minimal
impact since all participants received a full clinical con-
sultation at the time of cohort entry and the median
time to incident TB in was almost six months after en-
rolment. Despite the sensitivity analyses showing no dif-
ferences in interpretation of models whether all TB
cases or only proven TB cases were included, it may be
possible that the associations we observed are only rele-
vant to some forms of TB (i.e. PTB vs. EPTB). Although
unavailable for this study, it would also be of interest to
consider viral load in these associations.
Conclusions
Our evidence suggests that iron redistribution reflecting a
shift from the periphery to the macrophage storage site is a
risk factor for incident TB among people with HIV co-
infection. Given the pattern of iron redistribution evident
in this study, it is unlikely that dietary iron insufficiency
was the primary cause of low hemoglobin concentrations
and therefore, supplemental iron to correct anemia would
be unlikely to reduce the risk of developing TB. Identifying
individuals at greater risk of TB using iron status biomar-
kers may lead to improved TB clinical and nutritional man-
agement, particularly for difficult to diagnose HIV and
pediatric TB, and earlier diagnoses resulting in faster TB
treatment may reduce TB transmission. Understanding
host-Mtb interactions and the biological mechanisms
underlying our observations may reveal exploitable targets
for future pharmaceutical and nutritional interventions that
will improve care of people living with Mtb and HIV co-
infection who are at risk of developing TB.
Additional files
Additional file 1: Rationale for study hypothesis.
Additional file 2: Baseline characteristics of participants.
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